Holen Sie sich die Stockscreener-App
79.42
1.74%
-1.41
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CVS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$80.83
Offen:
$81
24-Stunden-Volumen:
6.32M
Relative Volume:
0.85
Marktkapitalisierung:
$100.82B
Einnahmen:
$393.94B
Nettoeinkommen (Verlust:
$428.00M
KGV:
207.58
EPS:
0.3826
Netto-Cashflow:
$6.29B
1W Leistung:
+5.01%
1M Leistung:
-1.05%
6M Leistung:
+19.70%
1J Leistung:
+60.19%
1-Tages-Spanne:
$78.67
$81.08
1-Wochen-Bereich:
$75.00
$81.08
52-Wochen-Spanne:
$43.56
$85.15
Cvs Health Corp Stock (CVS) Company Profile
Firmenname
Cvs Health Corp
Sektor
Branche
Telefon
(401) 765-1500
Adresse
ONE CVS DR., WOONSOCKET
Vergleichen Sie CVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
79.42 | 102.61B | 393.94B | 428.00M | 6.29B | 0.3826 |
|
UNH
Unitedhealth Group Inc
|
341.84 | 305.02B | 435.16B | 18.37B | 17.37B | 19.16 |
|
ELV
Elevance Health Inc
|
359.07 | 80.05B | 194.82B | 5.53B | 3.77B | 24.45 |
|
CI
Cigna Group
|
274.70 | 72.73B | 268.22B | 6.55B | 7.44B | 22.67 |
|
HUM
Humana Inc
|
268.45 | 32.05B | 123.11B | 1.58B | 2.44B | 13.03 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | Goldman | Buy |
| 2025-08-18 | Hochstufung | UBS | Neutral → Buy |
| 2025-08-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Edward Jones | Hold → Buy |
| 2024-12-03 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-05-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-05-02 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-22 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Herabstufung | Edward Jones | Buy → Hold |
| 2023-05-26 | Eingeleitet | Piper Sandler | Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Eingeleitet | Goldman | Buy |
| 2021-12-01 | Eingeleitet | Seaport Research Partners | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-01-08 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-17 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-05-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-06-05 | Hochstufung | Standpoint Research | Hold → Buy |
| 2019-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Eingeleitet | Guggenheim | Buy |
| 2019-04-15 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-13 | Eingeleitet | Bernstein | Outperform |
| 2019-02-20 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-18 | Eingeleitet | Barclays | Overweight |
| 2018-11-29 | Fortgesetzt | Goldman | Neutral |
| 2018-11-28 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-26 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2018-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-02-27 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-02-13 | Bestätigt | Citigroup | Neutral |
Alle ansehen
Cvs Health Corp Aktie (CVS) Neueste Nachrichten
Putting pharmacy education within reach - CVS Health
CVS: Bernstein Raises Price Target for CVS Health to $87 | CVS S - GuruFocus
Bernstein raises CVS Health stock price target to $87 on Aetna growth potential - Investing.com
CVS Health Corporation $CVS is Camber Capital Management LP's 4th Largest Position - MarketBeat
CVS Health offering measles vaccine to South Carolina residents amid the state's current outbreak - Financial Times
Jim Cramer on CVS: "This Stock Has Become the Best Performer in the Healthcare Sector" - Finviz
Jim Cramer on CVS: “This Stock Has Become the Best Performer in the Healthcare Sector” - Insider Monkey
CVS Health (CVS) Receives Analyst Price Target Upgrade to $98 | - GuruFocus
CVS Health (CVS) Sees Analyst Rating Update from Piper Sandler | - GuruFocus
CVS Health Is Seeing Margin And App Momentum, Analyst Highlights - Benzinga
CVS Health Targets Steady Gains With A Revamped Game Plan - Finimize
CVS Health Stock (CVS) Opinions on 2025 Guidance Update - Quiver Quantitative
CVS Health (CVS) Analysts Maintain Overweight, Raise Price Targe - GuruFocus
UBS Maintains Buy Rating, Raises Price Target for CVS to $97 | C - GuruFocus
CVS Health Raises Its Long-Term Outlook And Stock Follows Suit - Finimize
CVS forecasts 2026 profit higher than Wall Street estimates - Providence Business News
CVS Health Corporation (CVS) Sees Higher Price Target Despite PBM Pressures - Insider Monkey
Mizuho Raises Price Target for CVS Health (CVS) to $95.00 | CVS Stock News - GuruFocus
CVS Health (NYSE:CVS) Price Target Raised to $98.00 at Truist Financial - MarketBeat
CVS Health (NYSE:CVS) Price Target Raised to $95.00 - MarketBeat
CVS Health (CVS) Receives Price Target Increase from Morgan Stan - GuruFocus
Cantor Fitzgerald reiterates Overweight rating on CVS Health stock - Investing.com
Piper Sandler raises CVS Health stock price target to $101 on growth outlook - Investing.com
CVS (CVS) Analyst Rating Update: Baird Raises Price Target to $9 - GuruFocus
CVS Health (NYSE:CVS) Given New $92.00 Price Target at Robert W. Baird - MarketBeat
Investment Management Corp of Ontario Has $5.74 Million Holdings in CVS Health Corporation $CVS - MarketBeat
Intact Investment Management Inc. Sells 20,100 Shares of CVS Health Corporation $CVS - MarketBeat
Morgan Stanley raises CVS Health stock price target to $93 on turnaround - Investing.com
RBC Capital reiterates Outperform rating on CVS Health stock with $93 target - Investing.com
Truist Securities raises CVS Health stock price target to $98 on upbeat outlook - Investing.com
Natixis Has $8.36 Million Stock Position in CVS Health Corporation $CVS - MarketBeat
CVS Health Corporation $CVS Shares Purchased by State Street Corp - MarketBeat
3 Reasons CVS is Risky and 1 Stock to Buy Instead - Finviz
CVS Health stock price target raised to $97 from $96 at UBS - Investing.com
BofA Securities reiterates Buy rating on CVS Health stock with $100 target - Investing.com
Daiwa Securities Group Inc. Purchases 37,509 Shares of CVS Health Corporation $CVS - MarketBeat
CVS Health stock price target raised to $95 by Mizuho on positive outlook - Investing.com
TD Cowen raises CVS Health stock price target to $105 on Medicare Advantage recovery - Investing.com
How Recent Shifts Are Rewriting the Story for CVS Health - Yahoo Finance
Ariel Investments LLC Purchases 144,541 Shares of CVS Health Corporation $CVS - MarketBeat
CVS Health Corporation (NYSE:CVS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
CVS raises profit forecast as turnaround plan takes effect - Honolulu Star-Advertiser
CVS forecasts 2026 profit above estimates as turnaround plan takes effect - Denver Gazette
CVS boosts profit outlook in sign of momentum as 2026 nears - The Boston Globe
CVS Health Hikes Its Outlook, and Says It Plans to Roll Out AI Platform - Investopedia
CVS Raises Profit Outlook in Sign of Momentum for 2026 - Transport Topics
Meet the 2.5% Yield Dividend Stock That Could Soar in 2026 - The Motley Fool
Is It Time to Bet on CVS Health? - StocksToTrade
CVS Health: Investor Day Targets Set Attractive Baseline For 2026 (CVS) - Seeking Alpha
CVS Forecasts 2026 Revenue Short of Wall Street Estimates - Bloomberg.com
Why CVS Health (CVS) Stock Is Up Today - Finviz
Finanzdaten der Cvs Health Corp-Aktie (CVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.32%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):